Multiple Bayesian Network Meta-Analyses to Establish Therapeutic Algorithms for Metastatic Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast tumors and is defined by the absence of endocrine receptors (ER) and HER2 gene overexpression/amplification.[1] Metastatic TNBC (mTNBC) remains an incurable disease with unfavorable prognosis[2]. However, the scenario is quickly changing. 10.6 - 41.9% TNBC harbor a germline mutation in the homologous recombination repair (HRR) genes BRCA1/2.[3] In these cases, following positive results from respective pivotal trials, it is now possible to administer the PARP-inhibitors (PARPi) olaparib or talazoparib in first or further lines.

Source: Cancer Treatment Reviews - September 27, 2022 Category: Cancer & Oncology Authors: Francesco Schettini, Sergio Venturini, Mario Giuliano, Matteo Lambertini, David J. Pinato, Concetta Elisa Onesti, Pietro De Placido, Nadia Harbeck, Diana L üftner, Hannelore Denys, Peter Van Dam, Grazia Arpino, Khalil Zaman, Giorgio Mustacchi, Joseph Gli Source Type: research